At 14 days post-transduction, however, we found that C9-ALS neurospheres treated with RfxCas13d-N2V8 had a ~35% decrease in CBLN1 mRNA compared to cells treated with the non-targeted crRNA (P < 0.001; Fig. 3k), with no change in its expression observed in the wild-type cells treated with PHP.eB-RfxCas13d-N2V8-crRNA-13 (P > 0.05; Fig. 3k). The gene discussed is CBLN1; the disease is amyotrophic lateral sclerosis.